Condition: B-Cell ALL · B-Cell Acute Lymphoblastic Leukaemia · B-Cell Lymphoblastic Leukemia · Sponsor: Arkansas Children's Hospital Research Institute
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity. Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.
This description comes directly from the study's public registry record.
Lauren Appell, MD · 501-364-1494 · leappell@uams.edu
Stephanie Thomas, RN · 501-364-3820
Always discuss trial participation with your own doctor first.
| Arkansas Children's | Little Rock, Arkansas, United States | Recruiting |
| Arkansas Children's Northwest | Springdale, Arkansas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07422337